Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study

Author:

Wang Xiaozeng1,Ma Dengfeng2,Li Tianchang3,Li Bao4,Su Xi5,Wu Yanqing6,Du Zhimin7,Ji Zheng8,Yang Ping9,Yang Baisong10,Cao Xuebin11,Li Junxia12,Hou Fengxia13,Cheng Ziping14,Xu Banglong15,Han Yaling1

Affiliation:

1. General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, China

2. Taiyuan Center Hospital, Taiyuan, Shanxi 030009, China

3. Navy General Hospital of Chinese People’s Liberation Army, Beijing 100048, China

4. Shanxi Cardiovascular Hospital, Taiyuan, Shanxi 30001, China

5. Wuhan Asia Heart hospital, Wuhan, Hubei 430022, China

6. The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330012, China

7. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510120, China

8. Tangshan Gongren Hospital, Tangshan, Hebei 063000, China

9. China-Japan Union Hospital of Jilin University, Changchun, Jilin 130031, China

10. Air Force Hospital of Northern Theater Command, Shenyang, Liaoning110042, China

11. Hospital 252 of Chinese People’s Liberation Army, Baoding, Hebei 071066, China

12. General Hospital of Chinese People’s Liberation Army, Beijing 100853, China

13. Changchun Central Hospital, Changchun, Jilin 130051, China

14. The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China

15. The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, China.

Abstract

Objective: This study aimed to evaluate the major adverse cardiovascular and cerebrovascular events (MACCEs) and overall safety profile associated with iodixanol in Chinese patients undergoing percutaneous coronary intervention (PCI). Methods: Patients at 30 centers in China registered in the OpenClinic v3.6 database from October 30, 2013, to October 7, 2015, were included in the study. The primary endpoint was in-hospital MACCEs including target lesion revascularization (TLR), stroke, stent thrombosis, cardiac death, and PCI-related myocardial infarction (MI) within 72 h post-PCI. Secondary endpoints were MACCEs from 72 h to 30 d post-PCI and other safety events within 30 d post-PCI. Results: A total of 3,042 patients were enrolled. The incidence of MACCEs within 72 h post-PCI was 2.33% (n = 71), including cardiac death (0.03%, n = 1) and PCI-related MI (2.30%, n = 70). The incidence of MACCEs from 72 h to 30 d post-PCI was 0.16% (n = 5), including cardiac death (0.10%, n = 3), PCI-related MI (0.03%, n = 1), and TLR for stent thrombosis (0.03%, n = 1). The incidence of composite angiographic or procedural complications was 2.86% (n = 87); 233 (7.86%) patients had results suggesting contrast-induced acute kidney injury. Conclusions: These findings indicate that the use of iodixanol in Chinese patients undergoing PCI is associated with a low incidence of MACCEs, confirming its safety in this population.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference32 articles.

1. 2018 ESC/EACTS Guidelines on myocardial revascularization.;Neumann;Eur Heart J,2019

2. Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians; Editorial Board of Chinese Journal of Cardiology. Chinese guideline for percutaneous coronary intervention (2016).;Zhonghua Xin Xue Guan Bing Za Zhi,2016

3. Nephrotoxicity of iodixanol versus iopamidol in patients undergoing peripheral angiography with or without endovascular therapy.;Xiong;Int Urol Nephrol,2018

4. Influence of contrast media on thrombus formation during coronary angioplasty.;Gasperetti;J Am Coll Cardiol,1991

5. Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology.;Chronos;Circulation,1993

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3